Using the STING agonist ADU-S100, researchers showed that STING activation decreases cancer cell viability, increases immune-enhancing cytokines IFNβ and IL-6, and activates the TBK1/NF-κB pathway, boosting immune activity. This evidence concerns the gene NFKB1 and cancer.